Acadia reported that enrollment in the clinical trial is significantly ahead of schedule, which should enable the company to report results for the clinical trial during the first quarter of 2007, ahead of earlier expectations.
Given the rapid enrollment and opportunity to expedite results for the complete study, Acadia will no longer perform an interim analysis based on the first 200 patients, which had been planned to be conducted by the end of 2006.
The phase II clinical trial is a study designed to evaluate the ability of ACP-103 when used adjunctively with each of risperidone, an atypical antipsychotic drug, and haloperidol, a typical antipsychotic drug, to provide an improved therapy for patients with schizophrenia.
The primary endpoint of the study is antipsychotic efficacy as measured by the Positive and Negative Syndrome Scale (PANSS), an industry standard rating scale used in schizophrenia trials.
“We believe that adjunctive therapy with ACP-103 may result in both better efficacy and lower side effects than current treatments, thereby providing the potential to significantly improve the therapy for patients suffering from schizophrenia and related neuropsychiatric disorders,” said Roger Mills, Acadia’s executive vice president of development.